文章：

北欧国家前列腺癌条件生存率揭示改善时机

Conditional Survival in Prostate Cancer in the Nordic Countries Elucidates the Timing of Improvements

原文发布日期：16 August 2023

DOI: 10.3390/cancers15164132

类型: Article

开放获取: 是

英文摘要：

Background: The incidence of prostate cancer (PC) increased vastly as a result of prostate-specific antigen (PSA) testing. Survival in PC improved in the PSA-testing era, but changes in clinical presentation have hampered the interpretation of the underlying causes. Design: We analyzed survival trends in PC using data from the NORDCAN database for Denmark (DK), Finland (FI), Norway (NO) and Sweden (SE) by analyzing 1-, 5- and 10-year relative survival and conditional relative survival over the course of 50 years (1971–2020). Results: In the pre-PSA era, survival improved in FI and SE and improved marginally in NO but not in DK. PSA testing began toward the end of the 1980s; 5-year survival increased by approximately 30%, and 10-year survival improved even more. Conditional survival from years 6 to 10 (5 years) was better than conditional survival from years 2 to 5 (4 years), but by 2010, this difference disappeared in countries other than DK. Survival in the first year after diagnosis approached 100%; by year 5, it was 95%; and by year 10, it was 90% in the best countries, NO and SE. Conclusions: In spite of advances in diagnostics and treatment, further attention is required to improve PC survival.

摘要翻译： 

背景：前列腺特异性抗原（PSA）检测的广泛应用显著提高了前列腺癌（PC）的检出率。在PSA检测时代，前列腺癌患者的生存率有所改善，但临床表现的变化使得对其根本原因的解释变得复杂。设计：我们利用NORDCAN数据库中丹麦（DK）、芬兰（FI）、挪威（NO）和瑞典（SE）的数据，通过分析50年间（1971–2020年）的1年、5年和10年相对生存率以及条件相对生存率，来研究前列腺癌的生存趋势。结果：在PSA检测普及前，芬兰和瑞典的生存率有所提高，挪威略有改善，而丹麦则未见明显变化。PSA检测于20世纪80年代末开始应用；此后，5年生存率提高了约30%，10年生存率的改善更为显著。从第6年至第10年（5年）的条件生存率优于从第2年至第5年（4年）的条件生存率，但到2010年，除丹麦外，其他国家的这一差异已消失。在生存率表现最佳的挪威和瑞典，诊断后第一年的生存率接近100%，第五年达到95%，第十年达到90%。结论：尽管诊断和治疗手段有所进步，仍需进一步关注以提高前列腺癌的生存率。

原文链接：

Conditional Survival in Prostate Cancer in the Nordic Countries Elucidates the Timing of Improvements